When Your Name on the Label Becomes a License Requirement

In today’s pharmaceutical industry, companies can face state licensing requirements in jurisdictions where they do not manufacture, ship, sell, distribute, or maintain a physical presence. In some cases, the deciding factor is not what a company does in a state, but whether a product with their label is consumed by a patient in that state.

For virtual manufacturers, that reality can come as a surprise.

These companies typically control a product’s brand, regulatory strategy, and commercialization while outsourcing manufacturing, packaging, warehousing, and distribution to qualified third-party partners.

The Virtual Manufacturer business model allows companies to bring products to market without maintaining their own manufacturing or distribution infrastructure. But it also creates regulatory complexity. Even when a virtual manufacturer never physically handles or distributes product, regulators may still view the company as a responsible supply chain participant because of its role as the label holder.

In some jurisdictions, simply appearing on a product label will determine whether a state expects licensure.

Why States Care About the Label

For many regulators, the label represents accountability, and that is where assumptions can break down for companies.

The label identifies the party associated with a product and often becomes a focal point when questions arise involving recalls, product quality, traceability, or supply chain oversight.

The Guidance Problem: Clear Answers in Some States, Gray Areas in Others

State Boards of Pharmacy do not apply a uniform approach to this issue.

State boards such as Connecticut, Texas, and Arizona provide relatively clear guidance on when a virtual manufacturer or label holder must be licensed. Others decline to offer interpretive guidance and instead refer companies back to statutes, rules, and regulations.

The challenge is that many of these frameworks were built around traditional pharmaceutical business models and do not clearly account for virtual manufacturers or title model structures. Some regulators simply have not kept up with how the industry has evolved to become more efficient(i.e. outsourcing of manufacturing overseas).

Requirements can also vary depending on how a state defines terms such as manufacturer, wholesaler, virtual manufacturer, labeler, or third-party logistics provider.

As a result, companies are often left operating in gray areas where licensing obligations are not always clearly defined.

How DSCSA Increased the Focus on Supply Chain Accountability

The Drug Supply Chain Security Act (DSCSA) did not create label holder licensing obligations, but it reinforced the industry’s focus on traceability and accountability throughout the pharmaceutical supply chain.

As supply chain transparency has increased, regulators have become more attentive to the parties associated with a product, including companies that may never physically handle products, but still appear on labeling, documentation, or supply chain records.

Why This Matters in Practice

For companies, this is not simply a technical compliance issue. It can affect planning, timelines, budgets, and product launches.

Label holder obligations can surface unexpectedly, particularly in virtual manufacturers. Some companies discover late in the initial commercialization process that they may have licensing exposure in states where they assumed none existed. Others spend significant time interpreting rules that do not provide definitive answers.

That is why this area often requires early analysis and proactive planning.

In today’s regulatory environment, a company’s compliance footprint is no longer defined solely by where it manufactures, ships, or sells. Increasingly, accountability follows the role a company plays in the supply chain, and for virtual manufacturers, a name on the label can become a trigger that some organizations don’t expect.

Are your products ending up in states where you aren’t currently licensed?

LighthouseAI specializes in helping pharmaceutical supply chain companies navigate the complexity of state licensing requirements. Contact us today, and we’ll determine your licensing requirements and help close any compliance gaps for labeler states, otherwise known as Ends-Up-In states.